Table 3 General features of the trials which were included in this analysis
Trials | Type of study | Patients enrollment period | No of patients using 100 mg CANA (n) | No of patients using 300 mg CANA (n) | Trial number |
|---|---|---|---|---|---|
Blonde 2016 [9] | RCT | 2009-2013 | 724 | 721 | NCT00968812 + NCT01106651 |
Forst 2014 [10] | RCT | 2010-2012 | 113 | 114 | NCT01106690 |
Neal 2015 [11] | RCT | 2009-2011 | 692 | 690 | NCT01032629 |
Gonzalez 2013 [12] | RCT | 2010-2012 | 368 | 367 | NCT01106677 |
Inagaki 2013 [13] | RCT | 2009-2010 | 74 | 75 | NCT01022112 |
Inagaki 2014 [14] | RCT | 2011-2012 | 127 | 253 | NCT01387737 |
Stenlof 2013 [15] | RCT | 2010-2012 | 195 | 197 | NCT01081834 |
Wilding 2013 [16] | RCT | 2010-2012 | 157 | 156 | NCT01106625 |
Yale 2013 [17] | RCT | - | 90 | 89 | - |
Rosenstock 2012 [18] | RCT | 2008–2009 | 64 | 128 | NCT00642278 |
Total no | 2604 | 2790 |